Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial.

Toleva O, Westerhout CM, Senaratne MP, Bode C, Lindroos M, Sulimov VA, Montalescot G, Newby LK, Giugliano RP, Van de Werf F, Armstrong PW.

Catheter Cardiovasc Interv. 2014 Nov 15;84(6):934-42. doi: 10.1002/ccd.25590. Epub 2014 Jul 9.

PMID:
24976083
2.

Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.

Pride YB, Mohanavelu S, Zorkun C, Kunadian V, Giugliano RP, Newby LK, Braunwald E, Califf RM, Harrington RA, Gibson CM; EARLY ACS Investigators.

JACC Cardiovasc Interv. 2012 Sep;5(9):927-35. doi: 10.1016/j.jcin.2012.05.007.

3.

Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.

Vavalle JP, Clare R, Chiswell K, Rao SV, Petersen JL, Kleiman NS, Mahaffey KW, Wang TY.

JACC Cardiovasc Interv. 2013 Jul;6(7):709-17. doi: 10.1016/j.jcin.2013.03.010.

4.

Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

Nikolsky E, McLaurin BT, Cox DA, Manoukian SV, Xu K, Mehran R, Stone GW.

JACC Cardiovasc Interv. 2012 Sep;5(9):919-26. doi: 10.1016/j.jcin.2012.06.009.

5.

Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.

Hess CN, Schulte PJ, Newby LK, Steg PG, Dalby AJ, Schweiger MJ, Lewis BS, Armstrong PW, Califf RM, van de Werf F, Harrington RA.

Eur Heart J Acute Cardiovasc Care. 2013 Sep;2(3):246-55. doi: 10.1177/2048872612474922.

6.

Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.

Chan MY, Mahaffey KW, Sun LJ, Pieper KS, White HD, Aylward PE, Ferguson JJ, Califf RM, Roe MT.

JACC Cardiovasc Interv. 2008 Aug;1(4):369-78. doi: 10.1016/j.jcin.2008.03.019. Erratum in: JACC Cardiovasc Interv. 2008 Oct;1(5):600-1.

7.

Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.

Lopes RD, White JA, Tricoci P, White HD, Armstrong PW, Braunwald E, Giugliano RP, Harrington RA, Lewis BS, Brogan GX Jr, Gibson CM, Califf RM, Newby LK.

Int J Cardiol. 2013 Sep 10;167(6):2580-7. doi: 10.1016/j.ijcard.2012.06.053. Epub 2012 Jul 13.

PMID:
22795720
8.

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Théroux P, Stone GW, Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA.

Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):448-58. doi: 10.1161/CIRCOUTCOMES.110.960294. Epub 2011 Jun 28. Review.

9.

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).

Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA.

Am J Cardiol. 2015 May 15;115(10):1325-32. doi: 10.1016/j.amjcard.2015.02.043. Epub 2015 Feb 18.

PMID:
25776457
10.

Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.

Singh KP, Roe MT, Peterson ED, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, Smith SC Jr, Gibler WB, Ohman EM, Pollack CV Jr; CRUSADE Investigators.

J Thromb Thrombolysis. 2006 Jun;21(3):211-20.

PMID:
16683212
11.

Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.

Bagai A, White JA, Lokhnygina Y, Giugliano RP, Van de Werf F, Montalescot G, Armstrong PW, Tricoci P, Gibson CM, Califf RM, Harrington RA, Newby LK.

Am Heart J. 2013 Sep;166(3):466-73. doi: 10.1016/j.ahj.2013.05.019. Epub 2013 Jul 25.

PMID:
24016495
12.

Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals.

Roe MT, Chen AY, Delong ER, Boden WE, Calvin JE Jr, Cairns CB, Smith SC Jr, Pollack CV Jr, Brindis RG, Califf RM, Gibler WB, Ohman EM, Peterson ED.

Am Heart J. 2008 Jul;156(1):185-92. doi: 10.1016/j.ahj.2008.01.033. Epub 2008 Apr 14.

PMID:
18585515
13.
14.

Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Ebrahimi R, Dyke C, Mehran R, Manoukian SV, Feit F, Cox DA, Gersh BJ, Ohman EM, White HD, Moses JW, Ware JH, Lincoff AM, Stone GW.

J Am Coll Cardiol. 2009 May 26;53(21):1965-72. doi: 10.1016/j.jacc.2009.03.006.

15.

Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial.

Kaul P, Tanguay JF, Newby LK, Hochman JS, Westerhout CM, Califf RM, Tricoci P, Gibson CM, Giugliano RP, Harrington RA, Van de Werf F, Armstrong PW.

Am Heart J. 2013 Oct;166(4):723-8. doi: 10.1016/j.ahj.2013.07.014. Epub 2013 Sep 5.

PMID:
24093853
16.

A risk score to predict bleeding in patients with acute coronary syndromes.

Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW.

J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66. doi: 10.1016/j.jacc.2009.09.076.

17.

Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators.

N Engl J Med. 2009 May 21;360(21):2176-90. doi: 10.1056/NEJMoa0901316. Epub 2009 Mar 30.

19.

Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.

Chew DP, Huang Z, Pieper KS, White H, Mahaffey KW, Ferguson JJ, Califf RM, Aylward PG.

Am Heart J. 2008 Feb;155(2):239-44. doi: 10.1016/j.ahj.2007.10.002. Epub 2007 Nov 26.

PMID:
18215592
20.

Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization.

Elbarasi E, Goodman SG, Yan RT, Welsh RC, Kornder J, Wong GC, Déry JP, Anderson F, Gore JM, Fox KA, Yan AT; Canadian Acute Coronary Syndrome Registries I and II (ACS I and ACS II); Canadian Global Registry of Acute Coronary Events (GRACE/expanded-GRACE) Investigators.

Am Heart J. 2010 Jan;159(1):40-6. doi: 10.1016/j.ahj.2009.09.019.

PMID:
20102865
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk